Literature DB >> 32856229

Pediatric Hepatocellular Carcinoma.

Fatma İlknur Varol1.   

Abstract

PURPOSE: Pediatric hepatocellular carcinoma is rarely seen in childhood. It constitutes approximately 1% of childhood solid organ malignancies. Pediatric hepatocellular carcinoma is the second most common malignant liver tumor after hepatoblastoma in children. In this review, we aimed to review the diagnosis and treatment of pediatric hepatocellular carcinoma in the light of the latest literature.
METHODS: We reviewed the literature in terms of the diagnosis and treatment of pediatric hepatocellular carcinoma.
RESULTS: Hepatocellular carcinoma (HCC) and hepatoblastoma constitute 0.5-1.5% of all childhood malignant tumors. HCC is responsible for 27% of all liver tumors and 4% of all pediatric liver transplantations. While 99.6% of HCC is seen in adults, only 0.4% of it is seen in pediatric patients. Etiological predisposition and biological behavior are different from adults. In a child with cirrhosis or liver disease, HCC should be suspected in the presence of a high level of AFP and an abnormal nodule on ultrasonography. Hepatoblastoma should be considered first in the differential diagnosis.
CONCLUSION: Treatment of pediatric HCC is challenging. Complete surgical resection is essential for the cure. To this end, different neoadjuvant chemotherapy protocols have been designed to convert non-resectable tumors into resectable tumors. For tumors that cannot be resected, liver transplantation for each patient with childhood HCC should be decided individually.

Entities:  

Keywords:  Hepatoblastoma; Hepatocellular carcinoma; Pediatric

Mesh:

Year:  2020        PMID: 32856229     DOI: 10.1007/s12029-020-00494-w

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  3 in total

1.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

2.  Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein.

Authors:  Zhen-Peng Jiang; Ke-Yu Zeng; Jia-Yan Huang; Jie Yang; Rui Yang; Jia-Wu Li; Ting-Ting Qiu; Yan Luo; Qiang Lu
Journal:  World J Gastroenterol       Date:  2022-06-07       Impact factor: 5.374

3.  Circular RNA circ SET domain containing 2 (circSETD2) inhibits hepatocellular carcinoma cell proliferation and invasion in vivo and in vitro.

Authors:  Keyan Sun; Lei Zhang; Peng Chen; Debin Qi; Hao Liu; Haili Bao; Xiongwei Wang; Tao Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.